Showing 681-690 of 1365 results for "".
- Dermatologist Dr. Jill Waibel Selected as Keynote Speaker for Orlando Dermhttps://practicaldermatology.com/news/dermatologist-dr-jill-waibel-selected-as-keynote-speaker-for-orlando-derm/2458759/Laser expert and dermatologist Jill S. Waibel, MD, will provide the keynote speech, "Lasers for Trauma Rehabilitation: Giving Humans the Power to Heal Themselves," at the Orlando Dermatology Aesthetic and Clinical Conference (ODAC). Dr. Waibel was recently featured in national news cove
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- Rock Creek Pharmaceuticals Adds KOLs to Enhance Dermatological Disease Programhttps://practicaldermatology.com/news/rock-creek-pharmaceuticals-adds-kols-to-enhance-dermatological-disease-program/2458794/Rock Creek Pharmaceuticals, Inc., a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, has retained two Key Opinion Leaders (KOLs), each having renowned international expertise in dermatological d
- Lumenis UltraPulse Technology is Being Used to Treat Kim Phuc “The Girl in the Picture”https://practicaldermatology.com/news/lumenis-ultrapulse-technology-is-being-used-to-treat-kim-phuc-the-girl-in-the-picture/2458821/Lumenis Ltd.’s UltraPulse laser is being used by Jill Waibel, MD to treat scars on Kim Phuc, a survivor of a Vietnam War bombing in 1972. The UltraPulse was chosen for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars. Kim Phuc, a
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- Dermira: Kathleen Sebelius Elected to Board of Directorshttps://practicaldermatology.com/news/dermira-kathleen-sebelius-elected-to-board-of-directors/2458861/Dermira, Inc. has elected Kathleen Sebelius, the 21st U.S. Secretary of Health and Human Services, to its board of directors. "We are honored and excited to welcome Kathleen Sebelius to Dermira's board of directors,&quo
- DermTube Kicks Off Video Coverage of SAAD in New Yorkhttps://practicaldermatology.com/news/dermtube-kicks-off-video-coverage-of-saad-in-new-york/2458889/With the American Academy of Dermatology meeting currently underway in New York, Practical Dermatology® magazine and DermTube have begun their joint video coverage of the event, with video interview with key opinion leaders. Su
- SCOTUS Upholds Affordable Care Act in King v. Burwell Ruling; AADA and AMA Issue Statementshttps://practicaldermatology.com/news/scotus-upholds-affordable-care-act-in-king-v-burwell-ruling-aada-and-ama-issue-statements/2458920/In a 6-3 ruling in King v. Burwell, the US Supreme Court upheld tax subsidies for the Affordable Care Act. Steven J. Stack, MD, President of the American Medical Association release a statement on the decision, saying “The American Medical Association (AMA) is relieved that today&rs
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti
- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drughttps://practicaldermatology.com/news/kythera-biopharmaceuticals-announces-fda-approval-of-kybellatm-also-known-as-atx-101-first-and-only-submental-contouring-injectable-drug/2458953/KYTHERA Biopharmaceuticals, Inc. (Nasdaq: